BIOPSYCHOSOCIAL APPROACHES TO OBSESSIVE-COMPULSIVE, BODY IMAGE AND EATING DISORDERS
Dr Nicola Acevedo, Neuroscientist and Research Fellow
Swinburne University of Technology, Melbourne, Australia
& Consultant, Neurotech Insights, Melbourne, Australia &
Director, BioAutism, Melbourne, Australia & Vice-President
Australasian Brain Stimulation Society
RESEARCHER PROFILE
Filmed in Melbourne, Australia | December 2025
Dr Nicola Acevedo is a Neuroscientist and Research Fellow with extensive expertise in developing novel therapeutics for neurological and psychiatric disorders, contributing to more than ten clinical trials. She specialises in brain stimulation and psychedelic treatments for obsessive-compulsive disorder (OCD) and related conditions, with a strong commitment to advancing personalised, evidence-based neurobiological therapies for severe psychiatric illness. Her approach integrates biopsychosocial and person-centred principles to improve treatment access and mental health outcomes.
Nicola completed her PhD on deep brain stimulation for treatment-refractory OCD- described as a “tour de force”- producing eight first-author peer-reviewed publications and multiple international collaborations and papers. She now leads research in psilocybin-assisted psychotherapy for OCD, body dysmorphic disorder, and anorexia nervosa. Her work has been presented at leading international forums including Oxford and Harvard University, and the Royal Australian and New Zealand College of Psychiatrists Congress.
Alongside her research, Nicola holds leadership positions across brain stimulation, OCD, and ethics committees, serves on a peer review board, and is Director of the charity BioAutism Ltd. She also provides mentorship and supervision, with a commitment to supporting junior researchers. Her contributions have been recognised with the Early Career Researcher (ECR) Excellence Award from Biological Psychiatry Australia. As an ECR, Nicola is driven by the potential to innovate and make an impact in national mental health services.
Source: Supplied
https://orcid.org/0000-0003-3059-3620
-
Nanoparticles & microparticles to combat antimicrobial resistance
Dr Anjana Jayasree is an emerging research leader in biomaterials, tissue engineering and nanotechnology, recognised internationally for her innovative work on antimicrobial nanoparticles and regenerative therapies. A Postdoctoral Research Fellow at The University of Queensland, she operates at the intersection of materials science, drug delivery and cellular biology, developing advanced metallic-based nanotechnologies to improve both human and animal health outcomes. Her expertise spans nanoparticle synthesis, cell–material interactions, and the design of sophisticated in vitro models to investigate soft-tissue integration, osseointegration, angiogenesis and biofilm formation.
-
Neonatal respiratory trials in sick & preterm newborn infants
Prof Brett J. Manley leads and collaborates on large national and international randomised clinical trials in neonatology. He previously collaborated on 4 randomised trials of nasal high-flow as non-invasive respiratory support for preterm and term infants, all of which were published in N Engl J Med. Recently he led the PLUSS trial of intratracheal budesonide for extremely preterm infants, that recruited in 21 NICUs across 4 countries, the results of which were published in JAMA. PLUSS was awarded the Australian Clinical Trials Alliance Trial of the Year in 2025. Another passion of his is mentoring and supervising early career researchers to undertake their own clinical trials.
-
Next-generation NK cell-based immunotherapies for hard-to-treat cancers
Associate Professor Fernando Guimaraes is an internationally recognised leader in cancer immunotherapy and natural killer (NK) cell biology. Based at The University of Queensland, he leads innovative research focused on developing next-generation NK cell-based immunotherapies for hard-to-treat cancers, including sarcomas and neuroblastoma.
